JP2023510918A - Ｍａｐ４ｋ１阻害剤 - Google Patents

Ｍａｐ４ｋ１阻害剤 Download PDF

Info

Publication number
JP2023510918A
JP2023510918A JP2022543496A JP2022543496A JP2023510918A JP 2023510918 A JP2023510918 A JP 2023510918A JP 2022543496 A JP2022543496 A JP 2022543496A JP 2022543496 A JP2022543496 A JP 2022543496A JP 2023510918 A JP2023510918 A JP 2023510918A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
cycloalkyl
alkyl
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022543496A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023510918A5 (cg-RX-API-DMAC10.html
Inventor
ブルベイカー，ジェイソン・ディー
ミドゥツル，チャンドラセクハー・ブイ
バーク，マイケル・ジェイ
ディニーン，トーマス・エイ
キム，ジョセフ・エル
クローズ，ジョシュア・ティー
ペローラ，エマニュエル
Original Assignee
ブループリント メディシンズ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブループリント メディシンズ コーポレイション filed Critical ブループリント メディシンズ コーポレイション
Publication of JP2023510918A publication Critical patent/JP2023510918A/ja
Publication of JP2023510918A5 publication Critical patent/JP2023510918A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022543496A 2020-01-15 2021-01-14 Ｍａｐ４ｋ１阻害剤 Pending JP2023510918A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062961463P 2020-01-15 2020-01-15
US62/961,463 2020-01-15
PCT/US2021/013359 WO2021146370A1 (en) 2020-01-15 2021-01-14 Map4k1 inhibitors

Publications (2)

Publication Number Publication Date
JP2023510918A true JP2023510918A (ja) 2023-03-15
JP2023510918A5 JP2023510918A5 (cg-RX-API-DMAC10.html) 2024-01-23

Family

ID=74557263

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022543496A Pending JP2023510918A (ja) 2020-01-15 2021-01-14 Ｍａｐ４ｋ１阻害剤

Country Status (7)

Country Link
US (2) US11534441B2 (cg-RX-API-DMAC10.html)
EP (1) EP4090663A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023510918A (cg-RX-API-DMAC10.html)
CN (1) CN115279771B (cg-RX-API-DMAC10.html)
AR (1) AR121047A1 (cg-RX-API-DMAC10.html)
TW (1) TW202140473A (cg-RX-API-DMAC10.html)
WO (1) WO2021146370A1 (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
PH12022551574A1 (en) 2019-12-23 2024-02-26 Blueprint Medicines Corp Egfr inhibitors
EP4090663A1 (en) 2020-01-15 2022-11-23 Blueprint Medicines Corporation Map4k1 inhibitors
JP2024510176A (ja) * 2021-03-08 2024-03-06 ブループリント メディシンズ コーポレイション Ｍａｐ４ｋ１阻害剤
CN117295748A (zh) * 2021-03-08 2023-12-26 缆图药品公司 Map4k1抑制剂
CN117836286A (zh) 2021-06-22 2024-04-05 缆图药品公司 用于治疗癌症的杂环egfr抑制剂
MX2024000751A (es) * 2021-07-14 2024-03-25 Blueprint Medicines Corp Compuestos heterociclicos como inhibidores de map4k1.
US20240336630A1 (en) * 2021-07-15 2024-10-10 Blueprint Medicines Corporation Map4k1 inhibitors
CN114940683B (zh) * 2022-07-26 2023-01-17 轩竹(北京)医药科技有限公司 Hpk1抑制剂及其用途
WO2024196841A1 (en) * 2023-03-21 2024-09-26 Athos Therapeutics, Inc. Vanin-1 inhibitors
CN121548580A (zh) * 2023-05-15 2026-02-17 亚历克西亚治疗公司 Cdk抑制剂化合物
WO2025080099A1 (ko) * 2023-10-13 2025-04-17 주식회사유한양행 7,7-다이메틸푸로[3,4-b]피리딘-5(7h)-온 유도체 또는 이의 염 및 이를 포함하는 약학 조성물

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532486A (ja) * 2006-04-06 2009-09-10 ノバルティス アーゲー Ｐｄｋ１阻害のためのキナゾリン類
JP2015527387A (ja) * 2012-09-07 2015-09-17 キャンサー・リサーチ・テクノロジー・リミテッド 阻害剤化合物
JP2015529657A (ja) * 2012-08-07 2015-10-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ プロテインキナーゼ阻害剤としてのピリドピリミジン誘導体
WO2018102366A1 (en) * 2016-11-30 2018-06-07 Ariad Pharmaceuticals, Inc. Anilinopyrimidines as haematopoietic progenitor kinase 1 (hpk1) inhibitors
WO2018183956A1 (en) * 2017-03-30 2018-10-04 Genentech, Inc. Naphthyridines as inhibitors of hpk1
JP2021531311A (ja) * 2018-07-24 2021-11-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ナフチリジン化合物およびその使用
JP2021532109A (ja) * 2018-07-24 2021-11-25 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト イソキノリン化合物及びその使用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
DK1879573T3 (da) 2005-05-10 2013-02-25 Incyte Corp Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2007041511A2 (en) 2005-09-30 2007-04-12 New York University Hematopoietic progenitor kinase 1 for modulation of an immune response
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
CA2663057C (en) 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US9603848B2 (en) 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
WO2012020742A1 (ja) 2010-08-10 2012-02-16 塩野義製薬株式会社 新規複素環誘導体およびそれらを含有する医薬組成物
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
NO2694640T3 (cg-RX-API-DMAC10.html) 2011-04-15 2018-03-17
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
GB201120993D0 (en) 2011-12-06 2012-01-18 Imp Innovations Ltd Novel compounds and their use in therapy
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
TW201542538A (zh) 2013-07-16 2015-11-16 奇尼塔公司 抗病毒化合物、醫藥組合物及其使用方法
JP6899323B2 (ja) 2014-10-14 2021-07-07 ラ ホーヤ インスティテュート オブ アレルギー アンド イミュノロジー 低分子量タンパク質チロシンホスファターゼの阻害剤、及びその使用
EP3270694A4 (en) 2015-02-17 2018-09-05 Neupharma, Inc. Certain chemical entities, compositions, and methods
US20180072718A1 (en) * 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
EP3652174A4 (en) 2017-07-13 2021-06-30 Syros Pharmaceuticals, Inc. TAM KINASE INHIBITORS
WO2021000935A1 (en) 2019-07-04 2021-01-07 Qilu Regor Therapeutics Inc. Hpk1 inhibitors and uses thereof
PH12022551574A1 (en) 2019-12-23 2024-02-26 Blueprint Medicines Corp Egfr inhibitors
EP4090663A1 (en) 2020-01-15 2022-11-23 Blueprint Medicines Corporation Map4k1 inhibitors
JP2024510176A (ja) 2021-03-08 2024-03-06 ブループリント メディシンズ コーポレイション Ｍａｐ４ｋ１阻害剤
MX2024000751A (es) 2021-07-14 2024-03-25 Blueprint Medicines Corp Compuestos heterociclicos como inhibidores de map4k1.

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532486A (ja) * 2006-04-06 2009-09-10 ノバルティス アーゲー Ｐｄｋ１阻害のためのキナゾリン類
JP2015529657A (ja) * 2012-08-07 2015-10-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ プロテインキナーゼ阻害剤としてのピリドピリミジン誘導体
JP2015527387A (ja) * 2012-09-07 2015-09-17 キャンサー・リサーチ・テクノロジー・リミテッド 阻害剤化合物
WO2018102366A1 (en) * 2016-11-30 2018-06-07 Ariad Pharmaceuticals, Inc. Anilinopyrimidines as haematopoietic progenitor kinase 1 (hpk1) inhibitors
WO2018183956A1 (en) * 2017-03-30 2018-10-04 Genentech, Inc. Naphthyridines as inhibitors of hpk1
JP2021531311A (ja) * 2018-07-24 2021-11-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ナフチリジン化合物およびその使用
JP2021532109A (ja) * 2018-07-24 2021-11-25 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト イソキノリン化合物及びその使用

Also Published As

Publication number Publication date
US11534441B2 (en) 2022-12-27
US20230140954A1 (en) 2023-05-11
US20220323438A1 (en) 2022-10-13
TW202140473A (zh) 2021-11-01
US12042495B2 (en) 2024-07-23
AR121047A1 (es) 2022-04-13
EP4090663A1 (en) 2022-11-23
CN115279771A (zh) 2022-11-01
CN115279771B (zh) 2025-03-21
WO2021146370A1 (en) 2021-07-22

Similar Documents

Publication Publication Date Title
US12042495B2 (en) MAP4K1 inhibitors
TWI879811B (zh) 作為免疫調節劑之吡啶并[3,2-d]嘧啶化合物
CN114728950B (zh) 可作为helios蛋白质抑制剂的化合物
TWI851563B (zh) 作為免疫調節劑之雜環化合物
CN110831600B (zh) 吲哚ahr抑制剂和其用途
CN110582493B (zh) 作为免疫调节剂的苯并噁唑衍生物
CN115605466B (zh) 用于治疗癌症的经取代的氧代异吲哚啉化合物
TW202016078A (zh) 作為介白素-1活性之抑制劑之磺醯脒（sulfonimidamide）化合物
TW201934548A (zh) 甲醯胺化合物及其用途
CN119241499A (zh) 3-(5-羟基-1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
JP2024510176A (ja) Ｍａｐ４ｋ１阻害剤
US12202844B2 (en) MAP4K1 inhibitors
CN121969613A (zh) 经取代的氮杂环丁烷基氧代异吲哚啉基哌啶-2,6-二酮化合物
CN117157286A (zh) 经吡啶基取代的氧代异吲哚啉化合物
WO2023288264A1 (en) Map4k1 inhibitors
CN117295748A (zh) Map4k1抑制剂
HK40121672A (en) Heteroaryl heterocyclic compounds and uses thereof
EA048583B1 (ru) Пиридинил-замещенные оксоизоиндолиновые соединения для лечения злокачественной опухоли
CN117396477A (zh) 用于治疗癌症的经吡啶基取代的氧代异吲哚啉化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241224

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250616